1523027-75-9

Upstream product

• 1620069-18-2 N-(2,2-dimethoxyethyl)-2-(3-nitrophenyl)acetimidamide 
• 621-50-1 (3-nitrophenyl)acetonitrile 

Downstream Products

• 1620068-81-6 (S)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide 
• 1620068-90-7 (S)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)isonicotinamide 
• 1620068-91-8 (S)-2-([1,1'-biphenyl]-4-yl)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)acetamide 
• 1620068-92-9 (S)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)-[1,1'-biphenyl]-4-carboxamide 
• 1620068-93-0 (S)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)-[1,1'-biphenyl]-2-carboxamide 
• 1620068-94-1 (S)-1-acetyl-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)piperidine-4-carboxamide 
• 1620068-95-2 (S)-2-((2-cyanophenyl)thio)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)benzamide 
• 1620068-97-4 (S)-2,2-bis(4-chlorophenyl)-N-(3-((1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)acetamide 
• 1620069-01-3 (3,4-dichloropheny)-3-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)urea 
• 1620069-02-4 (S)-1-(3-chlorophenyl)-3-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)urea 
• 1620068-82-7 (S)-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)-3,5-dimethylbenzamide 
• 1620069-03-5 C₂₅H₂₃ClF₃N₇O₂ 
• 1620069-04-6 C₃₂H₃₈F₃N₉O₂ 
• 1620068-83-8 C₂₂H₂₂N₈O₂ 

Relevant academic research and scientific papers

Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient

The present invention relates to a novel imidazole-1-yl pyrimidine derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutic composition comprising the same. Since the imidazole-1-yl pyrimidine derivative according to the present inventio

Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors

The synthesis of a novel series of (4-aminobenzyl/benzoyl)-1H-imidazol-1-yl pyrimidin-2-yl derivatives 9, 10, 18, 19 and their in vitro antiproliferative activities against the A375P human melanoma cell line and the U937 human leukemic monocyte lymphoma cell line are described. Potent antiproliferative effects were found from 9l, 9s and 10c; 10c was found to be a highly potent and selective BRAF V600E and CRAF inhibitor (IC50 = 38.3 nM and 8.79 nM).